WHO ICTRP trial
Parallel-group comparative study to evaluate the effect of high-dose…
JPRN-jRCTs031220373 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCTs031220373 |
|---|---|
| Public title | Parallel-group comparative study to evaluate the effect of high-dose nicotinamide mononucleotide (NMN) on aging |
| Scientific title | Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the effect of high-dose nicotinamide mononucleotide (NMN) on aging |
| Primary sponsor | Yamauchi Toshimasa |
| Secondary sponsors | MIRAILAB BIOSCIENCE Inc |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Conditions | Older adults who do not take medicine older adults;D000368;older adults |
| Interventions | Participants will be randomized in 2 groups: NMN 1,250 mg (5 tablets of 250 mg) orally, once a day, 24 weeks Placebo (5 tablets) orally, once a day, 24 weeks;D016449;Nicotin Amide Mononucleotide (NMN) |
| Registration date | Nov 10, 2022 |
| Target size | 62 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: